Impact Analysis of Covid-19 The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters. Request Sample

Pulmonary Arterial Hypertension (PAH) Market – Market Insights

Pulmonary Arterial Hypertension (PAH) is a rare disease, which affects the pulmonary arteries. High blood pressure in the lungs is called pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). It is characterized by narrowed and blocked arteries and capillaries. This rare disease usually grows worse over the period and may result to death if left untreated.

Market players are focusing on collaborations & mergers to develop novel products in the pulmonary arterial hypertension (PHA) market, which is expected to boost growth of the market over the forecast period. For instance, in 2017, Bayer AG and Vectura Group Plc. extended their collaboration to develop an upgraded version of nebulizer Breelib, which improves the efficacy of iloprost aerosol therapy for pulmonary atrial hypertension. Moreover, according to the National Institute of Health, the nebulizer is still in clinical trial and the study is expected to finish by March 2020.

Furthermore, ongoing regulatory approvals for the products by the market players is expected to fuel the market growth over the forecast period. For instance, in March 2016, Actelion Pharmaceuticals Ltd, the Janssen Pharmaceutical Companies of Johnson & Johnson Services Inc., received the approval for Uptravi (selexipag) for the treatment of pulmonary arterial hypertension. The Medicines and Medical Devices Safety Authority (Medsafe) approved the drug in the New Zealand and the Therapeutic Goods Administration (TGA) approved in Australia.

The global pulmonary arterial hypertension (PAH) market was valued at US$ 5,821.90 million in 2018, and is expected to exhibit a CAGR of 5.9% over the forecast period (2019-2027).

Figure 1. Global Pulmonary Arterial Hypertension (PHA) Market Value (US$ Mn), by Region, 2018

Source: Coherent Market Insights Analysis (2019)

Rising cases of heart problems leading to pulmonary arterial hypertension (PHA) is expected to boost growth of the global pulmonary arterial hypertension (PHA) market

The global pulmonary arterial hypertension (PHA) market is expected to witness significant growth over the forecast period, owing to rising cases of heart disorders, which leads to pulmonary arterial hypertension (PHA). For instance, according to the Center for Disease Control and Prevention (CDC), a report- Prevalence of uncontrolled risk factors for cardiovascular disease – May 2019 states that, in the U.S. someone has a heart attack every 40 seconds. The report also states that each year, around 805,000 people in the U.S. have a heart attack.

Figure 2. Global Pulmonary Arterial Hypertension (PHA) Market Share (%), by Drug Type, 2019 and 2027

Source: Coherent Market Insights Analysis (2019)

Increasing collaborations for novel product development and rising cases of pulmonary hypertensions are expected to drive the market growth

North America is expected to hold a dominant position in the global pulmonary arterial hypertension (PHA) market, owing to increasing strategic partnerships and collaborations by key players, which is expected to drive the North America market growth over the forecast period. For instance, in September 2018, United Therapeutics entered into a collaboration with MannKind Corporation for the development and commercialization of dry powder formulation of treprostinil. These companies also aimed to enter in a research agreement for the conduct of research by MannKind. This research was had to be performed by Mannkind on behalf of United Therapeutics for products outside the scope of the licensing and collaboration agreement.

Moreover, Europe is expected to be the second dominating region in the global pulmonary arterial hypertension (PHA) market, owing to rising cases of pulmonary arterial hypertension (PHA) in the region. For instance, according to the Health and Social Care Information Centre, National Audit of Pulmonary Hypertension - 2015, the study published in 2016 reports that 57.0% of patients were treated with pulmonary hypertension drug therapy in Great Britain, 56.0% in England, 63.0% in Scotland, and 73.0% in Wales.

Key Players

Major players operating in the global pulmonary arterial hypertension (PHA) market include United Therapeutics Corporation, GlaxoSmithKline plc, Novartis AG, AstraZeneca, Bayer AG, Merck KGaA, Pfizer Inc., Gilead Sciences, Inc., Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, and Daiichi Sankyo Company, Limited.